Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Arthur Tzianabos Resumes Chairman of the Board Role BEDFORD, Mass., October 06, 2025 BUSINESS WIRE )--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its Board of Directors has appointed Ian F. Smith as Chief Executive Officer (CEO). Mr. Smith has served as Interim CEO since March 2025 and as a member of Stoke's Board of Directors and advisor to the Company since 2023. He will continue to serve as a Director on the Company's Board of Directors. Arthur Tzianabos, Ph.D., has been a member of the Board of Directors since 2018. He will resume his role as Chairman of the Board after serving as Executive Chairman while the CEO search was conducted. A global Phase 3 study of the Company's lead investigational medicine, zorevunersen, is underway. Zorevunersen is a first-in-class potential disease-modifying medicine for Dravet syndrome. Dravet syndrome is a
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual MeetingBusiness Wire
- Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]Seeking Alpha
- Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual MeetingBusiness Wire
- Biotechs Are On A Big Run, And Two Stocks Have Buy Points [Yahoo! Finance]Yahoo! Finance
STOK
Earnings
- 11/4/25 - Miss
STOK
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- STOK's page on the SEC website